Pull to refresh
Logo
Daily Brief
Following
Why Sign Up
Jeff Shuren

Jeff Shuren

Director, FDA Center for Devices and Radiological Health

Appears in 1 story

Stories

The blood test revolution in Alzheimer's diagnosis

New Capabilities

Oversaw approval of first Alzheimer's blood tests

For decades, diagnosing Alzheimer's meant either a $5,000 brain scan with radiation exposure or a painful spinal tap. In October 2025, the FDA cleared Roche's blood test for use in primary careβ€”a simple blood draw that rules out Alzheimer's 97.9% of the time. It's the second blood test approved in five months, transforming a diagnosis that once required specialists and imaging centers into something your family doctor can order.

Updated Jan 9